Cancer Chemotherapy Market Report Key Highlights

• Global cancer chemotherapy market revenue is estimated to reach USD 106 Billion by 2030 with a CAGR of 11.5% from 2022 to 2030
• According to the World Health Organization, over 10 million people died due to cancer in 2020
• North America cancer chemotherapy market occupied over 47% regional shares in 2021
• In 2021, the United States recorded more than 1.9 million new cancer cases and 608,570 cancer deaths
• Asia-Pacific cancer chemotherapy market is likely to attain a substantial CAGR from 2022 to 2030
• Based on indication segment, breast cancer acquired more than 20% of the total market share in 2021
• Growing incidences of cancer in the world propels the cancer chemotherapy market growth in coming years

Chemotherapy refers to the drug treatment that uses powerful chemicals particularly to kill fast-growing cells inside the body. The factor is primarily making it a suitable procedure for cancer treatment, where these drugs are used alone or in combination to treat a wide variety of cancers. Additionally, these are used in various conditions like to cure cancer without other treatments or as a primary or sole treatment for cancer, for killing hidden cancer cells, and utilized to prepare for other treatments by shrinking a tumor so that other treatments, such as radiation and surgery, are possible. Additionally, it can also be used to ease the signs and symptoms of cancer by killing some of the cancer cells.

Global Cancer Chemotherapy Market Dynamics

Market Drivers

• Rising prevalence of cancer
• Growing lethargic life habits and changing lifestyle
• Increasing research & development activities

Market Restraints

• High cost of this treatment
• Adverse health effects of this treatment

Market Opportunities

• Growing expenditure on oncology
• Favorable health insurance and reimbursement policies

Cancer Chemotherapy Market Report Coverage

Cancer Chemotherapy Market Insights

The rising prevalence of cancer disease across all age demographics around the globe is the primary factor driving the chemotherapy market growth. The changing lifestyle, rapid urbanization, and unhealthy life habits are boosting the number of cancer patients across the globe. According to the National Cancer Institute (the US National Institutes of Health), an estimated 1,806,590 new cases of cancer were diagnosed in the US and 606,520 people died from the disease in 2020. The most common cancer are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. Furthermore, the rising awareness about the treatment in developing economies, increasing expenditure on oncology medicine and research, reimbursements, and growing health insurance are further expected to create growth patterns over the forecast period.

On the other side, the high cost associated with drug development and treatment is likely to hinder the growth to an extent over the forecast period from 2022 to 2030.

Cancer Chemotherapy Market Segmentation

The worldwide cancer chemotherapy market is split based on indication, drug class, route of administration, and geography.

Cancer Chemotherapy Market By Indication

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Lymphoma
• Leukemia
• Ovarian Cancer
• Others

Breast cancer accounted for a significant market revenue in 2021, according to our cancer chemotherapy industry analysis. According to the WHO, there will be 2.3 million women diagnosed with breast cancer in 2020, with 685 000 deaths worldwide. As of the end of 2020, 7.8 million women had been diagnosed with breast cancer in the previous five years, making it the world's most common cancer. According to the American Cancer Society, approximately 287,850 new instances of invasive breast cancer will be diagnosed in women, with approximately 43,250 women dying from the disease.

Cancer Chemotherapy Market By Drug Class

• Alkylating Agents
• Mitotic Inhibitors
• Antimetabolites
• Topoisomerase Inhibitors
• Antitumor Antibiotic
• Others

Alkylating agents accounted for a sizable market share in 2021 and are expected to continue to do so in the coming years. Alkylating agents were the first anti-cancer prescription medications and are still among the most frequently used chemotherapy agents today. Alkylating agents cause cross-linking of DNA strands, unusual base pairing, or DNA strand breaks, preventing the cell from dividing. Alkylating agents are generally thought to be cell cycle phase nonspecific, which means they kill cells at multiple stages of the cell cycle.

Cancer Chemotherapy Market By Route of Administration

• Intravenous
• Oral
• Subcutaneous
• Intra-Muscular Intravesicular
• Topical
• Intraperitoneal
• Intraventricular/Intrathecal
• Others

According to our cancer chemotherapy market forecast, the intravenous route of administration subsegment accounted for the greatest market share from 2022 to 2030. Chemotherapy is typically administered via vein infusion (intravenously). The drugs can be administered by inserting a needle-tipped tube into a vein in patient’s arm or a device into a vein in their chest.

Cancer Chemotherapy Market By End-User

• Hospitals & Clinics
• Specialty Centers
• Others

In 2021, hospitals and clinics accounted for a maximum cancer chemotherapy market share and is expected to continue its dominace during the projected timeframe. The high growth in the sub-segment is credited to the precise treatment of cancer in hospitals, presence of skilled medical professionals, existence of advanced healthcare equipment, and favorable reimbursement policies.

Cancer Chemotherapy Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Latin America

• Mexico
• Brazil
• Rest of Latin America

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

The Middle East & Africa (MEA)

• Gulf Cooperation Council (GCC)
• South Africa
• Rest of the Middle East & Africa

North America accounted for the maximum revenue share in the global market

In 2021, North America held the major share in terms of both revenue and the number of people treated. The region is also projected to maintain its dominance over the forecast period from 2022 to 2030. The major economy of the region US accounted for the maximum revenue share (%) in terms of revenue (US$ Bn). The rapidly increasing number of patients in the region is primarily supporting the growth. Additionally, the presence of a high-income base population which is able to spend on the treatment is further bolstering the regional market value. Moreover, the presence of technologically advanced infrastructure is further propelling the regional market value.

Asia Pacific is anticipated to experience fastest growth over the forecast timeframe from 2020 to 2027

The Asia-Pacific is anticipated to experience the fastest growth over the forecast period from 2022 to 2030 due to its advancing healthcare sector and increasing disposable income. The rapidly growing economies of the region including China and India are the major revenue contributors. The rising awareness about the treatment in the developing economies as well as the increasing spending power of people is further accelerating the market value.

Cancer Chemotherapy Market Players

The global cancer chemotherapy companies profiled in the report include Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson Indication Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi S.A. among others.